Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
Loading...
Embargo End Date
ICR Authors
Authors
Ronchi, C
Brisken, C
Brisken, C
Document Type
Journal Article
Date
2023-03-01
Date Accepted
2022-12-22
Abstract
The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elía et al., p. 866.
Citation
Clinical Cancer Research, 2022, pp. CCR-22-3374 -
Source Title
Clinical Cancer Research
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1078-0432
eISSN
1557-3265
1557-3265
1557-3265
Collections
Research Team
Endocrine control mechans